Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


01.01.2018

1 Am J Surg
3 Ann Oncol
1 Cancer
2 Cancer Chemother Pharmacol
1 Cancer Res
1 Clin Cancer Res
2 Curr Opin Obstet Gynecol
2 Gynecol Oncol
1 J Natl Cancer Inst
3 Oncol Rep
3 PLoS One
1 Semin Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. LABGAA I, Slankamenac K, Schadde E, Jibara G, et al
    Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: A multicentric study.
    Am J Surg. 2018;215:125-130.
    PubMed     Text format     Abstract available


    Ann Oncol

  2. FRIEDLANDER M, Rau J, Lee CK, Meier W, et al
    Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters - patient centered endpoints in trials of maintenan
    Ann Oncol. 2017 Dec 18. pii: 4756055. doi: 10.1093.
    PubMed     Text format     Abstract available

  3. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Text format     Abstract available

  4. MANGILI G, Sigismondi C, Lorusso D, Cormio G, et al
    The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    Cancer

  5. LE GALLO M, Rudd ML, Urick ME, Hansen NF, et al
    The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30971.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  6. YOSHIKAWA T, Takano M, Miyamoto M, Yajima I, et al
    Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers.
    Cancer Chemother Pharmacol. 2017;80:555-561.
    PubMed     Text format     Abstract available

  7. CORTEZ AJ, Tudrej P, Kujawa KA, Lisowska KM, et al
    Advances in ovarian cancer therapy.
    Cancer Chemother Pharmacol. 2017 Dec 16. pii: 10.1007/s00280-017-3501.
    PubMed     Text format     Abstract available


    Cancer Res

  8. KANG J, Shin SH, Yoon H, Huh J, et al
    FIH is an oxygen sensor in ovarian cancer for G9a/GLP-driven epigenetic regulation of metastasis-related genes.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-2506.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  9. TUCKER DW, Getchell CR, McCarthy ET, Ohman AW, et al
    Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Clin Cancer Res. 2017 Dec 20. pii: 1078-0432.CCR-17-1958.
    PubMed     Text format     Abstract available


    Curr Opin Obstet Gynecol

  10. VOLPE J, Filipi JG, Cooper OR, Penson RT, et al
    Frontline therapy of ovarian cancer: trials and tribulations.
    Curr Opin Obstet Gynecol. 2018;30:1-6.
    PubMed     Text format     Abstract available

  11. MCCANN KE
    Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    Curr Opin Obstet Gynecol. 2018;30:7-16.
    PubMed     Text format     Abstract available


    Gynecol Oncol

  12. TRAN AQ, Erim DO, Sullivan SA, Cole AL, et al
    Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31598.
    PubMed     Text format     Abstract available

  13. MIAO M, Deng G, Luo S, Zhou J, et al
    A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31596.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  14. VISVANATHAN K, Wang TL, Shih IM
    Precancerous Lesions of Ovarian Cancer-A US Perspective.
    J Natl Cancer Inst. 2017 Dec 21. pii: 4769851. doi: 10.1093.
    PubMed     Text format    


    Oncol Rep

  15. LIU L, Wang X, Li X, Wu X, et al
    Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
    Oncol Rep. 2018;39:818-826.
    PubMed     Text format     Abstract available

  16. ZHANG N, Qiu J, Zheng T, Zhang X, et al
    Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6159.
    PubMed     Text format     Abstract available

  17. HU H, Huang G, Wang H, Li X, et al
    Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis.
    Oncol Rep. 2017 Dec 15. doi: 10.3892/or.2017.6158.
    PubMed     Text format     Abstract available


    PLoS One

  18. KUROKI LM, Jin X, Dmitriev IP, Kashentseva EA, et al
    Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.
    PLoS One. 2017;12:e0190125.
    PubMed     Text format     Abstract available

  19. COUTTENIER A, Lacroix O, Vaes E, Cardwell CR, et al
    Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.
    PLoS One. 2017;12:e0189233.
    PubMed     Text format     Abstract available

  20. OBATA T, Nakamura M, Mizumoto Y, Iizuka T, et al
    Dual expression of immunoreactive estrogen receptor beta and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    PLoS One. 2017;12:e0188641.
    PubMed     Text format     Abstract available


    Semin Oncol

  21. CAPOLUONGO E, Ellison G, Lopez-Guerrero JA, Penault-Llorca F, et al
    Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    Semin Oncol. 2017;44:187-197.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: